Treating pulmonary silicosis by blocking interleukin 1

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 5, 2015, Pages 596-598

  Cavalli, Giulio ^a   Fallanca, Federico ^b   Dinarello, Charles A ^a   Dagna, Lorenzo ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; CARBON MONOXIDE; CORTICOSTEROID; CRYOPYRIN; INTERLEUKIN 1BETA; OXYGEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN;

ADULT; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; BLOOD CULTURE; BREATHING RATE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE SEVERITY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GAIN OF FUNCTION MUTATION; GOUT; HOSPITALIZATION; HUMAN; LETTER; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG INFECTION; LUNG LAVAGE; LYMPHADENOPATHY; MALE; OFF LABEL DRUG USE; OXYGEN SATURATION; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRESSURE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SHORT FORM 36; SILICOSIS; VITAL CAPACITY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ADULT; ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RECOMBINANT PROTEINS; SILICOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84923902300     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201412-2150LE     Document Type: Letter

References (13)

1. Leung CC, Yu IT, Chen W. Silicosis. Lancet 2012;379:2008-2018.
2. Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep 2010;10:229-235.
3. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-677.
4. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008;105:9035-9040.
5. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-856.
6. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265.
7. Petsonk EL, Rose C, Cohen R. Coal mine dust lung disease. New lessons from old exposure. Am J Respir Crit Care Med 2013;187:1178-1185.
8. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-652.
9. Dinarello CA. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. Immunity 2004;20:243-244.
10. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J, Kullberg BJ, Netea MG, van der Meer JW. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009;68:273-278.
11. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012;36:388-400.
12. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013;25:469-484.
13. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-1684.